Teleflex Q3 revenue slightly beats estimates
Reuters2026/11/05 11:47
Overview
US medical device maker's Q3 revenue up 0.2% yr/yr, slightly beating analyst expectations
Adjusted diluted EPS for Q3 rose to $2.63, beating consensus
Company repurchased $350 mln in stock since July 1, 2026
Outlook
Teleflex maintains 2026 pro forma adjusted constant currency revenue growth guidance at 3.5%-4.5%
Company raises 2026 adjusted diluted EPS guidance to $7.50-$7.75 from continuing operations
Teleflex lowers 2026 GAAP revenue growth guidance to 13.2%-14.2% due to foreign exchange changes
Result Drivers
SEGMENT PERFORMANCE - Vascular and Surgical units delivered mid-single-digit growth, while Interventional returned to modest growth, per CEO Jason Weidman
TARIFF REFUNDS - Q3 results benefited from $16.5 mln in IEEPA tariff refunds recognized in continuing operations
MARGIN EXPANSION - Co cited margin expansion as contributing to robust EPS growth, even when excluding tariff refunds, per CEO Jason Weidman
Company press release: ID:nBwvY6jfa
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q3 Revenue |
Slight Beat* |
$567.78 mln |
$566.77 mln (11 Analysts) |
Q3 Adjusted EPS |
Beat |
$2.63 |
$1.90 (12 Analysts) |
Q3 EPS continuing operations |
|
$1.30 |
|
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Teleflex Incorporated is $155.00, about 3.4% above its November 4 closing price of $149.87
The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 15 three months ago
Reuters Recommended Reads
Nov 4 - Insulet Q3 revenue beats estimates on strong Omnipod sales
Nov 3 - AtriCure Q3 revenue beats expectations on strong sales of pain management and appendage devices
Nov 4 - LivaNova Q3 revenue beats estimates on cardiopulmonary segment strength
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
How does the shift in AI trends impact the forex market?

Traders expect the Bank of England to raise interest rates twice before March next year.

